Sigilon Therapeutics is a biotechnology business based in the US. Sigilon Therapeutics shares (SGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics employs 62 staff and has a trailing 12-month revenue of around $17.7 million.
Our top picks for where to buy Sigilon Therapeutics Inc stock
How to buy Sigilon Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – SGTX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Sigilon Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Sigilon Therapeutics stock price (NASDAQ: SGTX)
Use our graph to track the performance of SGTX stocks over time.Sigilon Therapeutics shares at a glance
Latest market close | $22.47 |
---|---|
52-week range | $0.00 - $0.00 |
50-day moving average | $17.35 |
200-day moving average | $10.36 |
Wall St. target price | $21.00 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-14.83 |
Is it a good time to buy Sigilon Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sigilon Therapeutics price performance over time
Historical closes compared with the close of $22.47 from 2023-08-18
1 week (2024-08-27) | N/A |
---|---|
1 month (2024-08-03) | N/A |
3 months (2024-06-03) | N/A |
6 months (2024-03-03) | N/A |
1 year (2023-09-03) | N/A |
---|---|
2 years (2022-09-07) | 3,449.76% |
3 years (2021-09-07) | 247.30% |
5 years (2019-09-03) | N/A |
Sigilon Therapeutics financials
Revenue TTM | $17.7 million |
---|---|
Gross profit TTM | $-24,687,000 |
Return on assets TTM | -23.65% |
Return on equity TTM | -76.31% |
Profit margin | -171.29% |
Book value | $10.97 |
Market Capitalization | $56.2 million |
TTM: trailing 12 months
Sigilon Therapeutics share dividends
We're not expecting Sigilon Therapeutics to pay a dividend over the next 12 months.
Have Sigilon Therapeutics's shares ever split?
Sigilon Therapeutics's shares were split on a 1:13 basis on 22 May 2023. So if you had owned 13 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sigilon Therapeutics shares – just the quantity. However, indirectly, the new 1200% higher share price could have impacted the market appetite for Sigilon Therapeutics shares which in turn could have impacted Sigilon Therapeutics's share price.
Sigilon Therapeutics share price volatility
Over the last 12 months, Sigilon Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sigilon Therapeutics's is 4.115. This would suggest that Sigilon Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Sigilon Therapeutics's beta into context you can compare it against those of similar companies.
- Sarepta Therapeutics (SRPT.US): 0.814
- Rubius Therapeutics (RUBY.US): 2.208
Sigilon Therapeutics overview
Sigilon Therapeutics, Inc. , a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc.
Frequently asked questions
What percentage of Sigilon Therapeutics is owned by insiders or institutions?Currently 8.69% of Sigilon Therapeutics shares are held by insiders and 54.329% by institutions. How many people work for Sigilon Therapeutics?
Latest data suggests 62 work at Sigilon Therapeutics. When does the fiscal year end for Sigilon Therapeutics?
Sigilon Therapeutics's fiscal year ends in December. Where is Sigilon Therapeutics based?
Sigilon Therapeutics's address is: 100 Binney Street, Cambridge, MA, United States, 02142 What is Sigilon Therapeutics's ISIN number?
Sigilon Therapeutics's international securities identification number is: US82657L1070
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 best brokerage accounts for buying stocks, options and more in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question